FDA accepts Opus Genetics presbyopia drug application Feb 25, 2026 06:59AM
LifeSci Capital Starts Opus Genetics (IRD) at Outperform Feb 12, 2026 07:48AM
Opus Genetics begins gene therapy trial for rare eye disease Jan 27, 2026 07:01AM
BTIG Starts Opus Genetics (IRD) at Buy Jan 20, 2026 05:06AM
Opus Genetics submits drug application, advances gene therapy trials Jan 8, 2026 07:07AM


Dec 10, 2025 01:11AM B.Riley Starts Opus Genetics (IRD) at Buy
Dec 1, 2025 08:46AM Brookline Capital Markets Starts Opus Genetics (IRD) at Buy
Nov 25, 2025 03:54AM Piper Sandler Starts Opus Genetics (IRD) at Overweight
Nov 6, 2025 07:03AM Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
Oct 29, 2025 06:54AM Wedbush Starts Opus Genetics (IRD) at Outperform
Oct 16, 2025 07:53AM Chardan Capital Markets Starts Opus Genetics (IRD) at Buy
Oct 1, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
Aug 18, 2025 08:01AM Opus Genetics receives FDA clearance for BEST1 gene therapy trial
Aug 13, 2025 06:13PM Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c
Jul 24, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
Jun 26, 2025 06:56AM Opus Genetics (IRD) Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint
Jun 25, 2025 05:19PM Opus Genetics (IRD) CFO departs; Amy Rabourn named interim principal financial officer
Jun 17, 2025 06:40AM Lucid Capital Markets Starts Opus Genetics (IRD) at Buy
Jun 2, 2025 08:00AM Opus Genetics (IRD) Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients
May 15, 2025 08:01AM Opus Genetics, Inc. (IRD) Tops Q1 EPS by 5c
May 6, 2025 08:03AM Opus Genetics (IRD) Granted FDA RMAT Designation for OPGx-LCA5 Gene Therapy Candidate
Apr 11, 2025 08:54AM Craig-Hallum Starts Opus Genetics (IRD) at Buy
Apr 8, 2025 08:01AM Opus Genetics (IRD) Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Apr 8, 2025 06:56AM Opus Genetics (IRD) Files for 19.38M Share Offering by Selling Stockholders
Apr 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
Mar 21, 2025 09:12AM Opus Genetics (IRD) Prices $20M Share Offering, Concurrent Private Placement with Proceeds of Over $20M
Mar 19, 2025 03:57PM Opus Genetics (IRD) reports inducement awards
Feb 26, 2025 08:04AM Opus Genetics (IRD) Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Feb 18, 2025 07:30AM Opus Genetics (IRD) Announces Updates on OPGx-LCA5 Clinical Program
Dec 19, 2024 08:01AM Opus Genetics (IRD) Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330
Nov 13, 2024 06:52AM H.C. Wainwright Assumes Opus Genetics (IRD) at Buy
Nov 12, 2024 08:04AM Opus Genetics, Inc. (IRD) Misses Q3 EPS by 4c